Quick Answer
Intellia Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $67.67 million for the year ending 2025.
- Intellia Therapeutics, Inc. showed an increase of +16.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Intellia Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 310.6%.
- Historical annual values: Fiscal year 2025: $67.67 million | Fiscal year 2024: $57.88 million | Fiscal year 2023: $36.28 million | Fiscal year 2022: $52.12 million | Fiscal year 2021: $33.05 million | Fiscal year 2020: $57.99 million | Fiscal year 2019: $43.10 million | Fiscal year 2018: $30.43 million | Fiscal year 2017: $26.12 million | Fiscal year 2016: $16.48 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: